Heart failure drug vericiguat under Real-World scrutiny in japan

NCT ID NCT06697353

Completed Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study analyzed data from nearly 5,000 Japanese patients with chronic heart failure who started taking vericiguat as part of their regular care. Researchers tracked outcomes like hospital stays and deaths over one year to see how the drug performs in everyday practice. The goal is to fill gaps in knowledge about vericiguat's use in Japanese patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vericiguat (Verquvo)
What this could lead to: If successful, this study could provide real-world evidence on how well vericiguat works in Japanese heart failure patients, helping doctors make better treatment decisions.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by other factors and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEART FAILURE CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION

Contacts and locations

Locations

Many Locations

Multiple Locations, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.